《Nature,2月5日,An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2021-02-25
  • An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study
    Zikun Yang, Paul Bogdan & Shahin Nazarian
    Scientific Reports volume 11, Article number: 3238 (2021)

    Abstract
    The rampant spread of COVID-19, an infectious disease caused by SARS-CoV-2, all over the world has led to over millions of deaths, and devastated the social, financial and political entities around the world. Without an existing effective medical therapy, vaccines are urgently needed to avoid the spread of this disease. In this study, we propose an in silico deep learning approach for prediction and design of a multi-epitope vaccine (DeepVacPred). By combining the in silico immunoinformatics and deep neural network strategies, the DeepVacPred computational framework directly predicts 26 potential vaccine subunits from the available SARS-CoV-2 spike protein sequence. We further use in silico methods to investigate the linear B-cell epitopes, Cytotoxic T Lymphocytes (CTL) epitopes, Helper T Lymphocytes (HTL) epitopes in the 26 subunit candidates and identify the best 11 of them to construct a multi-epitope vaccine for SARS-CoV-2 virus. The human population coverage, antigenicity, allergenicity, toxicity, physicochemical properties and secondary structure of the designed vaccine are evaluated via state-of-the-art bioinformatic approaches, showing good quality of the designed vaccine. The 3D structure of the designed vaccine is predicted, refined and validated by in silico tools.

  • 原文来源:https://www.nature.com/articles/s41598-021-81749-9
相关报告
  • 《BioRxiv,3月3日,Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus in China (SARS-CoV-2)》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-04
    • Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus in China (SARS-CoV-2) Ye Feng, Min Qiu, Shengmei Zou, Yun Li, Kai Luo, Rongchang Chen, Yingqiang Sun, Kui Wang, Xinlei Zhuang, Shanshan Zhang, Shuqing Chen, Fan Mo doi: https://doi.org/10.1101/2020.03.03.962332 Abstract A new coronavirus SARS-CoV-2, recently discovered in Wuhan, China, has caused over 74000 infection cases and 2000 deaths. Due to the rapidly growing cases and the unavailability of specific therapy, there is a desperate need for vaccines to combat the epidemic of SARS-CoV-2. In the present study, we performed an in silico approach based on the available virus genome to identify the antigenic B-cell epitopes and human-leukocyte-antigen (HLA) restricted T-cell epitopes. A total of 61 B-cell epitopes were initially identified, 19 of which with higher potential immunogenicity were used for vaccine design. *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.
  • 《Nature,12月28日,In silico discovery of antigenic proteins and epitopes of SARS-CoV-2 for the development of a vaccine or a diagnostic approach for COVID-19》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2021-02-01
    • In silico discovery of antigenic proteins and epitopes of SARS-CoV-2 for the development of a vaccine or a diagnostic approach for COVID-19 Hüseyin Can, Ahmet Efe Köseo?lu, Sedef Erkunt Alak, Mervenur Güvendi, Mert Dö?kaya, Muhammet Karakavuk, Adnan Yüksel Gürüz & Cemal Ün Scientific Reports volume 10, Article number: 22387 (2020) Abstract In the genome of SARS-CoV-2, the 5′-terminus encodes a polyprotein, which is further cleaved into 15 non-structural proteins whereas the 3′ terminus encodes four structural proteins and eight accessory proteins. Among these 27 proteins, the present study aimed to discover likely antigenic proteins and epitopes to be used for the development of a vaccine or serodiagnostic assay using an in silico approach. For this purpose, after the full genome analysis of SARS-CoV-2 Wuhan isolate and variant proteins that are detected frequently, surface proteins including spike, envelope, and membrane proteins as well as proteins with signal peptide were determined as probable vaccine candidates whereas the remaining were considered as possible antigens to be used during the development of serodiagnostic assays. According to results obtained, among 27 proteins, 26 of them were predicted as probable antigen. In 26 proteins, spike protein was selected as the best vaccine candidate because of having a signal peptide, negative GRAVY value, one transmembrane helix, moderate aliphatic index, a big molecular weight, a long-estimated half-life, beta wrap motifs as well as having stable, soluble and non-allergic features. In addition, orf7a, orf8, and nsp-10 proteins with signal peptide were considered as potential vaccine candidates. Nucleocapsid protein and a highly antigenic GGDGKMKD epitope were identified as ideal antigens to be used in the development of serodiagnostic assays. Moreover, considering MHC-I alleles, highly antigenic KLNDLCFTNV and ITLCFTLKRK epitopes can be used to develop an epitope-based peptide vaccine.